C E McCarron1, S Ernst2, J Q Cao2, G S Zaric1. 1. Ivey Business School at Western University, London, ON; 2. London Regional Cancer Program, London, ON.
Abstract
BACKGROUND: Fewer than half of all patients with metastatic melanoma survive more than 1 year. Standard treatments have had little success, but recent therapeutic advances offer the potential for an improved prognosis. In the present study, we used population-based administrative data to establish real-world baseline estimates of survival outcomes and costs against which new treatments can be compared. METHODS: Data from administrative databases and patient registries were used to find a cohort of patients with metastatic melanoma in Ontario. To identify individuals most likely to receive new treatments, we focused on patients eligible for second-line treatment. The identified cohort had two characteristics: no surgical resection beyond primary skin excision, and receipt of first-line systemic therapy. RESULTS: Patient characteristics, Kaplan-Meier survival curves, and mean costs are reported. Of the 33,585 patients diagnosed with melanoma in Ontario from 1 January 1991 to 31 December 2010, 278 met the study inclusion criteria. Average age was 63 years, and 62% of the patients were men. Overall survival was estimated to be 19%, 12%, and 6% at 12, 24, and 60 months respectively. Mean survival time was 11.5 months, and mean cost was $30,685. CONCLUSIONS: Our baseline estimates indicate that survival outcomes are poor and costs are high for patients receiving standard treatment. Understanding the relative improvement accruing from any new treatment requires a comparison with the existing standard of care.
BACKGROUND: Fewer than half of all patients with metastatic melanoma survive more than 1 year. Standard treatments have had little success, but recent therapeutic advances offer the potential for an improved prognosis. In the present study, we used population-based administrative data to establish real-world baseline estimates of survival outcomes and costs against which new treatments can be compared. METHODS: Data from administrative databases and patient registries were used to find a cohort of patients with metastatic melanoma in Ontario. To identify individuals most likely to receive new treatments, we focused on patients eligible for second-line treatment. The identified cohort had two characteristics: no surgical resection beyond primary skin excision, and receipt of first-line systemic therapy. RESULTS:Patient characteristics, Kaplan-Meier survival curves, and mean costs are reported. Of the 33,585 patients diagnosed with melanoma in Ontario from 1 January 1991 to 31 December 2010, 278 met the study inclusion criteria. Average age was 63 years, and 62% of the patients were men. Overall survival was estimated to be 19%, 12%, and 6% at 12, 24, and 60 months respectively. Mean survival time was 11.5 months, and mean cost was $30,685. CONCLUSIONS: Our baseline estimates indicate that survival outcomes are poor and costs are high for patients receiving standard treatment. Understanding the relative improvement accruing from any new treatment requires a comparison with the existing standard of care.
Authors: Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: K Johnston; A R Levy; P Lorigan; M Maio; C Lebbe; M Middleton; A Testori; C Bédane; C Konto; A Dueymes; U Sbarigia; M van Baardewijk Journal: Eur J Cancer Date: 2012-04-03 Impact factor: 9.162
Authors: Joan L Warren; Lisa Barbera; Karen E Bremner; K Robin Yabroff; Jeffrey S Hoch; Michael J Barrett; Jin Luo; Murray D Krahn Journal: J Natl Cancer Inst Date: 2011-05-18 Impact factor: 13.506
Authors: Nicole Mittmann; Ning Liu; Joan Porter; Soo Jin Seung; Pierre K Isogai; Refik Saskin; Matthew C Cheung; Natasha B Leighl; Jeffrey S Hoch; Maureen Trudeau; William K Evans; Katie N Dainty; Craig C Earle Journal: CMAJ Open Date: 2014-02-04
Authors: Nathaniel Jembere; Michael A Campitelli; Morris Sherman; Jordan J Feld; Wendy Lou; Stuart Peacock; Eric Yoshida; Murray D Krahn; Craig Earle; Hla-Hla Thein Journal: PLoS One Date: 2012-07-13 Impact factor: 3.240
Authors: D S Ernst; T Petrella; A M Joshua; A Hamou; M Thabane; S Vantyghem; F Gwadry-Sridhar Journal: Curr Oncol Date: 2016-12-21 Impact factor: 3.677
Authors: Malek B Hannouf; Eric Winquist; Salaheddin M Mahmud; Muriel Brackstone; Sisira Sarma; George Rodrigues; Peter K Rogan; Jeffrey S Hoch; Gregory S Zaric Journal: Pharmacoecon Open Date: 2018-09